Pharma BD Deal Intelligence

UCB S.A. / Antengene Corporation Limited

2026 · Licensing/Option · $1.2B · Complete

UCB and Antengene entered a global exclusive license agreement for ATG-201, a CD19/CD3 bispecific T-cell engager that uses steric hindrance masking technology to deplete CD19-expressing B cells in B cell-driven autoimmune disease. UCB receives worldwide rights to develop, manufacture and commercialize the asset plus access to the associated manufacturing technology. Terms: $80 million in upfront and near-term consideration, eligibility for more than $1.1 billion in development and commercial milestones, and tiered royalties on net sales. Antengene planned to file clinical trial applications in China and Australia in Q1 2026 and to complete first-in-human Phase 1 studies in both jurisdictions before transferring further development to UCB.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  UCB S.A. deals  ·  Immunology deals